Mr vaccines market

Q: Which region holds the largest market share in the market?

Asia Pacific holds the largest market share in the market. Read more

MR Vaccines Market, by Vaccine Brand (MR Vaccine and MRBEV (BE LTD.), by Distribution Channel (Private and Public), and by Region (Commonwealth of Independent States (CIS) Countries, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Request Free Sample

Feb 2022
CMI4917
154 Pages
Excel & Pdf
Biotechnology

Summary

The measles and rubella (MR) vaccine, which protects against measles and rubella, is recommended by the Centers for Disease Control and Prevention (CDC). MR vaccine should be given to children in two doses, the first at 12 to 15 months of age and the second at 4 to 6 years of age. Measles is a highly contagious virus that continues to be one of the leading vaccine-preventable causes of childhood death. High fever and severe skin rash are among the symptoms of measles. Rubella is a virus-borne infectious disease. Rubella causes a mild sickness in most people, with symptoms such as a low-grade fever, sore throat, and a rash that begins on the face and spreads to the rest of the body. The majority of people who are vaccinated against measles and rubella (MR) will be protected for the rest of their lives. Vaccines and high immunization rates have made these diseases much less common in the U.S.

The MR vaccines market is estimated to be valued at US$ 5 million in 2021 and is expected to exhibit a CAGR of 2.1% over the forecast period (2021-2028).

Figure 1. MR Vaccines Market Share (%), By Region, 2021

The increase in ongoing clinical trials is expected to drive growth of the MR vaccines market over the forecast period.

For instance, in November 2019, PT Bio Farma, an Indonesian state-owned enterprise, completed a Phase II / III clinical trial of Measles-Rubella (MR) vaccine. The study aimed to evaluate safety and immunogenicity of MR vaccine in Indonesian infants from 9 to 12 months of age.

MR Vaccines Market Report Coverage

Report Coverage	Details
Base Year:	2020	Market Size in 2021:	US$ 55.7 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2021 to 2028
Forecast Period 2021 to 2028 CAGR:	2.1%	2028 Value Projection:	US$ 79.2 Mn
Geographies covered:	Commonwealth of Independent States (CIS) Countries: Russia, Uzbekistan, Kazakhstan, Ukraine, Turkmenistan, Belarus, and Armenia Latin America: Brazil, Argentina, Mexico, Honduras, Colombia, Peru, and Chile Europe: Turkey Asia Pacific: Pakistan, Indonesia, Bangladesh, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Nepal, Sri Lanka, Papua New Guinea, and Mauritius Middle East: Israel, UAE, Iraq, Iran, Saudi Arabia, Jordan, Qatar, Oman, and Syrian Arab Republic Africa: South Africa, Nigeria, Tanzania, Democratic Republic of Congo, Ethiopia, Kenya, Egypt, Morocco, Ghana, Uganda, Burkina Faso, Angola, Algeria, Zimbabwe, Tunisia, Botswana, Libya, and Namibia
Segments covered:	By Vaccine Brand: MR Vaccine, MRBEV (BE LTD.) By Distribution Channel: Public, Private
Companies covered:	PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG
Growth Drivers:	The increasing cases of measles and rubella (MR) Increasing research and development activities and ongoing clinical trials for the development of safe MR vaccines Rising government initiatives to launch vaccine campaigns
Restraints & Challenges:	Risk of adverse reactions associated with measles and rubella (MR) vaccines

Figure 2. MR Vaccines Market Share (%), By Distribution Channel, 2021

The increasing government initiatives to launch vaccine campaigns is expected to drive the market growth over the forecast period.

For instance, in January 2020, the Ministry of Health and Family Welfare (MOHFW) launched Measles and Rubella vaccination campaign with support from UNICEF and World Health Organization (WHO). An objective of this campaign was to reach all children with age group 6 months to children less than 10 years at the Rohingya refugee camps of stateless Indo-Aryan people.

MR Vaccines Market– Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. While the COVID-19 measures such as social distancing, masks, and hand hygiene also minimized the spread of the measles virus.

For instance, according to the data published by World Health Organization (WHO), in November 2021, more than 22 million infants missed their first dose of measles vaccine throughout 2020 and more than 3 million in 2019. This resulted in a hike in measles incidence. In addition, 24 measles vaccination campaigns planned for 2020 in 23 countries, were postponed due to COVID-19 pandemic which left more than 93 million people at risk for the disease. Such campaigns are required for people who have missed out on measles-rubella vaccines. The COVID-19 pandemic made significant disruptions to immunization services and changes in health-seeking nature in many parts across the globe.

MR Vaccines Market Restraint

The risk of adverse reactions associated with measles and rubella (MR) vaccines are expected to hinder the growth of the MR vaccines market over the forecast period.

For instance, according to a report published by the U.S. National Library of Medicine in January 2021, adverse reactions related to Measles and Rubella vaccination are fever, followed by vomiting, abdominal pain, and dizziness. After 4-5 days of MR vaccine administration, few children may have abnormal body movements. In few cases, altered sensorium was detected on the same day as vaccine delivery.

Key Players

Major players operating in the MR vaccines market include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG.

Table of Content

*Browse 28 market data tables and 16 figures on "MR Vaccines Market” - Global forecast to 2028

Segmentation

Detailed Segmentation:

MR Vaccines Market, By Vaccine Brand:
- MR Vaccine
- MRBEV (BE LTD.)
MR Vaccines Market, By Distribution Channel:
- Public
- Private
MR Vaccines Market, By Region:
- Commonwealth of Independent States (CIS) Countries
  - By Vaccine Brand
    - MR Vaccine
    - MRBEV (BE LTD.)
  - By Distribution Channel
    - Public
    - Private
  - By Country
    - Russia
    - Uzbekistan
    - Kazakhstan
    - Ukraine
    - Turkmenistan
    - Belarus
    - Armenia
- Latin America
  - By Vaccine Brand
    - MR Vaccine
    - MRBEV (BE LTD.)
  - By Distribution Channel
    - Public
    - Private
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Honduras
    - Colombia
    - Peru
    - Chile
- Europe
  - By Vaccine Brand
    - MR Vaccine
    - MRBEV (BE LTD.)
  - By Distribution Channel
    - Public
    - Private
  - By Country
    - Turkey
- Asia Pacific
  - By Vaccine Brand
    - MR Vaccine
    - MRBEV (BE LTD.)
  - By Distribution Channel
    - Public
    - Private
  - By Country
    - Pakistan
    - Indonesia
    - Bangladesh
    - Philippines
    - Vietnam
    - Thailand
    - Myanmar
    - Malaysia
    - Cambodia
    - Nepal
    - Sri Lanka
    - Papua New Guinea
    - Mauritius
- Middle East
  - By Vaccine Brand
    - MR Vaccine
    - MRBEV (BE LTD.)
  - By Distribution Channel
    - Public
    - Private
  - By Country
    - UAE
    - Israel
    - Iraq
    - Iran
    - Saudi Arabia
    - Jordan
    - Qatar
    - Oman
    - Syrian Arab Republic
- Africa
  - By Vaccine Brand
    - MR Vaccine
    - MRBEV (BE LTD.)
  - By Distribution Channel
    - Public
    - Private
  - By Country/Region
    - Nigeria
    - Tanzania
    - Democratic Republic of Congo
    - Ethiopia
    - Kenya
    - South Africa
    - Egypt
    - Morocco
    - Ghana
    - Uganda
    - Burkina Faso
    - Angola
    - Algeria
    - Zimbabwe
    - Tunisia
    - Botswana
    - Libya
    - Namibia

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the MR vaccines market during the forecast period (2021-2028)?

The MR vaccines market size is estimated to be valued at US$ 55.7 million in 2021 and is expected to exhibit a CAGR of 2.1% between 2021 and 2028.

What are the major factors driving the market growth?

The increasing cases measles and rubella (MR), increasing research and development activities and ongoing clinical trials for the development of safe MR vaccines, rising government initiative to launch vaccine campaigns, and increasing adoption of inorganic growth strategies such partnerships by key players operating in the MR vaccines market with organizations such as WHO, UNICEF, and the GAVI Alliance are expected to drive the market growth over the forecast period.

Which is the leading vaccine brand segment in the market?

MR vaccine segment is expected to hold a major market share in the market.

Which region holds the largest market share in the market?

Asia Pacific holds the largest market share in the market.

What are the key factors hampering growth of the market?

Major factors hampering growth of the market include risk of adverse reactions associated with measles and rubella (MR) vaccines.

Which are the major players operating in the market?

Major players operating in the market include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG.